Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

  • RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    • News

  • BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    • News

  • AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    • News

  • Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    • News

  • Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    • News

  • FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    • News

  • Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    • News

Can fish oil make your baby smarter? Clover Corp trials could hold the answer

  • In News
  • March 21, 2022
  • Samantha Freidin
Can fish oil make your baby smarter? Clover Corp trials could hold the answer

Babies born before 37 weeks of pregnancy are considered premature, and often are at risk of getting sick or suffering developmental issues. Multiple studies have confirmed that there is an interplay between prematurity and childrens’ intelligence quotient (IQ). Premature babies often have lower IQs than their full term peers. 

To help premature babies reach their full potential, Clover Corporation (ASX: CLV) is developing a novel nutritional version of Docosahexaenoic Acid (DHA). DHA is an omega-3 fatty acid that is derived from fatty cold water fish such as salmon, or from seaweed. Omega-3 fatty acids can improve neurological functioning. It is also essential for the growth and functional development of the brain during infancy. 

Researchers at the South Australian Health and Medical Research Institute (SAHMRI) have been carrying out a clinical research study using Clover’s DHA. The N3RO trial has now been completed, having evaluated the potential benefits of Clover’s high DHA emulsion when used to support normal cognitive development of premature babies. 

Commencing back in 2012, the Trial saw infants born before 29 weeks enrolled and administered with Clover’s DHA alongside other standard of care treatments for premature babies. Numerous endpoint measures were evaluated. Further analysis of these results is underway, with the final report expected to determine next steps for the program’s direction. 

The Trial was funded in part by a grant from the National Health and Medical Research Council. Clover has invested over $1.2 million into product development and their people over the course of the project. 

A previous Phase 3 trial (DINO trial) by Clover informed the N3RO trial’s design. The DINO trial saw preterm babies receive DHA at differing doses. Those who received higher doses of DHA showed significant improvement in cognitive development, as well as reduced incidence of hay fever later in development. 

“We are encouraged in this early report of the top-line results from the study,” said Clover’s CEO and Managing Director Peter Davey. “We remain committed to better understanding the full data set as we consider potential paths forward for the DHA emulsion product. With strong clinical results from the previous DINO study and high tolerability of the DHA formulation we will continue to see a viable path forward for the development of DHA emulsions in this and wider clinical applications.” 

Whilst continuing research, Clover’s main business lies in the manufacture and sale of Omega 3 and 6 oil capsules. The Company provides their capsules to food, pharmaceutical and infant formula manufacturers. 

For the half year ended 31st January 2022 Clover reported a profit after tax of $2 million and paid a dividend of 0.5 cents per share. 

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  •  
  •  
  •  
  •  
  • asx clv
  • clover corporation
  • clv
  • dha
  • dino trial
  • omega 3
  • Peter Davey
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
  • How this company is developing medtech to support Indigenous community health - August 22, 2022
  • A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.